Prevalence of Vestibulocochlear Diseases and Depression: A systematic review

Ulises Saldaña Corona

doi:10.59706/aebmedicine.v2i1.10311

Authors

Ulises Saldaña Corona Benemérita Universidad Autónoma de Puebla https://orcid.org/0009-0009-5016-6037

DOI:

https://doi.org/10.59706/aebmedicine.v2i1.10311

Keywords:

Neurofibromatosis, Schwannoma vestibular, Neuroma acústico, depresión

Abstract

Background and purpose: Vestibular schwannomas (VS), along with conditions like neurofibromatosis type 1 (NF1) and type 2 (NF2), are studied in relation to the prevalence of depression in patients with vestibulocochlear disorders. This systematic review assessed depression using the Hospital Anxiety and Depression Scales (HADS) and the Beck Depression Inventory (BDI-IA).

Material and methods: A systematic review was conducted using the PubMed database with the search terms "Neurofibromatosis OR vestibular schwannoma OR acoustic neuroma AND depression." Inclusion criteria were case reports and series in English and Spanish, up to 2024, describing patients with NF1, NF2, or VS diagnosed with depression. Exclusion criteria included opinion articles, conference abstracts, reviews, and articles without relevant patient data. Depression was assessed using HADS and BDI-IA. Descriptive statistical analysis was performed using Microsoft Excel to calculate central tendency and percentages.

Results: Out of 66 initial articles, 25 met the inclusion criteria, with 8 selected for final analysis. These articles reported on a total of 2,443 patients from at least five countries. The prevalence of depression among patients with these conditions was found to be 40.90%. Other vestibulocochlear pathologies also manifested depressive symptoms, including Ménière's disease and vestibular neuritis.

Conclusions: The study highlights a significant prevalence of depression (40.90%) among patients with NF1, NF2, and VS. These findings underscore the substantial neuropsychological impact of eighth cranial nerve involvement and the necessity for psychiatric evaluations in this patient population. Future research should include previous psychiatric evaluations to provide a more comprehensive understanding of these diseases' neuropsychological effects.

Downloads

Download data is not yet available.

References

Gupta VK, Thakker A, Gupta KK. Vestibular Schwannoma: What We Know and Where We are Heading. Head and Neck Pathology. 2020 Mar 30;14(4):1058–66.

Kaul V, Cosetti MK. Management of Vestibular Schwannoma (Including NF2). Otolaryngologic Clinics of North America. 2018 Dec;51(6):1193–212.

Zanoletti E, Mazzoni A, d’Avella D. Hearing preservation in small acoustic neuroma: observation or active therapy? Literature review and institutional experience. Acta Neurochirurgica. 2018 Dec 8;161(1):79–83.

Eggermont JJ. Auditory brainstem response. Clinical Neurophysiology: Basis and Technical Aspects. 2019;451–64.

Carlson ML, Link MJ. Vestibular Schwannomas. Ingelfinger JR, editor. New England Journal of Medicine. 2021 Apr 8;384(14):1335–48.

Tin-Suet Joan Lee, Chopra M, Kim RH, Parkin PC, Barnett C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases. 2023 Sep 14;18(1).

Garcia B, Catasus N, Ros A, Rosas I, Negro A, Guerrero-Murillo M, et al. Neurofibromatosis type 1 families with first-degree relatives harbouring distinct NF1 pathogenic variants. Genetic counselling and familial diagnosis: what should be offered?. Journal of medical genetics. 2022 Feb 4;59(10):1017–23.

Moualed D, Wong J, Thomas O, Heal C, Saqib R, Choi C, et al. Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants. European Journal of Human Genetics [Internet]. 2022 Apr 1 [cited 2022 Oct 28];30(4):458–64. Available from: https://www.nature.com/articles/s41431-021-01029-y

Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine. 2022 Sep;24(9):1967–77.

Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2018 Jul;20(7):671–82.

Kallionpää RA, Uusitalo E, Leppävirta J, Pöyhönen M, Peltonen S, Peltonen J. Prevalence of neurofibromatosis type 1 in the Finnish population. Genetics in Medicine. 2017 Dec 7;20(9):1082–6.

Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. American Journal of Medical Genetics Part A [Internet]. 2010 Feb 1;152A(2):327–32. Available from: https://pubmed.ncbi.nlm.nih.gov/20082463/

Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Archives of Neurology [Internet]. 1988 May 1;45(5):575–8. Available from: https://pubmed.ncbi.nlm.nih.gov/3128965/

Zaleski-King A, Monfared A. Vestibular Migraine and Its Comorbidities. Otolaryngologic Clinics of North America. 2021 Oct;54(5):949–58.

Wang A, Fleischman KM, Kawai K, Corcoran M, Brodsky JR. Persistent Postural-Perceptual Dizziness in Children and Adolescents. Otology & Neurotology. 2021 Jun 4;42(8):e1093–100.

Herdman D, Sharma H, Simpson A, Murdin L. Integrating mental and physical health assessment in a neuro-otology clinic: feasibility, acceptability, associations and prevalence of common mental health disorders. Clinical Medicine. 2020 Jan;20(1):61–6.

Arroll M, Dancey CP, Attree EA, Smith S, James T. People With Symptoms of Ménière’s Disease. Otology & Neurotology. 2012 Jul;33(5):816–23.

András Molnár, Maihoub S, Panayiota Mavrogeni, László Tamás, Ágnes Szirmai. Depression scores and quality of life of vertiginous patients, suffering from different vestibular disorders. European Archives of Oto-Rhino-Laryngology. 2022 Apr 18;279(11):5173–9.

Ketola S, Havia M, Appelberg B, Kentala E. Psychiatric symptoms in vertiginous patients. Nordic Journal of Psychiatry. 2014 Nov 14;69(4):287–91.

Goto F, Nagisa Sugaya, Arai M, Masuda K. Psychiatric disorders in patients with intractable dizziness in the department of otolaryngology. Acta oto-laryngologica. 2018 Jan 31;138(7):646–7.

Zhu C, Li Y, Ju Y, Zhao X. Dizziness handicap and anxiety depression among patients with benign paroxysmal positional vertigo and vestibular migraine. Medicine [Internet]. 2020 Dec 24 [cited 2021 Aug 24];99(52):e23752. Available from: https://pubmed.ncbi.nlm.nih.gov/33350759/

Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica [Internet]. 1983;67(6):361–70. Available from: https://pubmed.ncbi.nlm.nih.gov/6880820/

Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. Journal of Psychosomatic Research. 2002 Feb;52(2):69–77.

Stern AF. The Hospital Anxiety and Depression Scale. Occupational Medicine [Internet]. 2014 Jul 1;64(5):393–4. Available from: https://academic.oup.com/occmed/article/64/5/393/1436876

López-Mejía R, Ramales-Montes EM, Ley-Silva LS, Romero-Sansalvador CY, Gutiérrez-Gabriel I. [Quality of life, depression and its relation to the severity in psoriasis]. Revista Medica Del Instituto Mexicano Del Seguro Social [Internet]. 2022 May 2;60(3):315–20. Available from: https://pubmed.ncbi.nlm.nih.gov/35763389/

Chibnall JT, Tait RC. The Short Form of the Beck Depression Inventory. The Clinical Journal of Pain. 1994 Dec;10(4):261–6.

Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro-Oncology Advances. 2020 Jan 10;2(Supplement_1):i141–9.

Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genetics in Medicine. 2012 Aug 9;14(12):977–82.

Best C. Interaction of somatoform and vestibular disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2006 May 1;77(5):658–64.

Møller P, Myrseth E, Pedersen P, Vassbotn F, Wentzel-Larsen T, Lund-Johansen M. Vestibular Schwannomas: An Evaluation of Clinical Results and Quality of Life after Microsurgery or Gamma-Knife Radiosurgery. Skull Base. 2005 Sep 20;15(S 2).

Sanna M, Taibah A, Russo A, Falcioni M, Agarwal M. Perioperative Complications in Acoustic Neuroma (Vestibular Schwannoma) Surgery. Otology & Neurotology. 2004 May;25(3):379–86.

Pollock BE, Lunsford DL, Kondziolka D, Flickinger JC, Bissonette DJ, Kelsey SF, et al. Outcome Analysis of Acoustic Neuroma Management: A Comparison of Microsurgery and Stereotactic Radiosurgery. Neurosurgery. 1995 Jan;36(1):215–29.

Lin EP, Crane BT. The Management and Imaging of Vestibular Schwannomas. American Journal of Neuroradiology. 2017 May 25;38(11):2034–43.

Friedman WA, Bradshaw P, Myers A, Bova FJ. Linear accelerator radiosurgery for vestibular schwannomas. Journal of Neurosurgery. 2006 Nov;105(5):657–61.

Cassandro C, Albera R, Debiasi L, Albera A, Cassandro E, Scarpa A, et al. What factors influence treatment decision making in acoustic neuroma? Our experience on 103 cases. The International Tinnitus Journal [Internet]. 2020 Nov 18 [cited 2022 Oct 26];24(1):21–5. Available from: https://pubmed.ncbi.nlm.nih.gov/33206494/